Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6 and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company